"The anti-rejection drug that has allowed my husband to go on for twelve years has now become unobtainable, the risk is that soon the whole island will lack that mycophenolic acid which transplant recipients cannot do without".
Thus begins the report of Emma Putzu , who first in the Frutti d'Oro pharmacy where she usually stocks up, then in that of the Brotzu hospital in Cagliari, was unable to find even a box of Accord 360, the drug that her husband Carlo has been hiring since he underwent a pancreas and kidney transplant twelve years ago.
Today the clarification on the matter of Ares Sardegna, which we report in full below.
***
With reference to the article that appeared today on the drug "Accord 360", the Health Department of ARES Sardegna specifies the following.
"As highlighted on the AIFA website, mycophenolic acid cp - Accord is included in the list of medicines lacking both for the 360 mg and 180 mg dosage.
However, at this time, the manufacturer Accord has ensured the continuity of treatments by making available the medicine with the lowest dosage: MYCOFEN ACID AC*100 CPR 180 MG.
The shortage of Mycophenolate 360mg cp has occurred several times in the past and, therefore, in 2020 the Region had to prepare a note authorizing pharmacies, in the absence of the 360 mg dosage and to ensure continuity of therapy, to distribute the 180 mg packaging .
The DPC office of ARES proceeded to place orders for MYCOFEN ACID AC*100CPR 180 MG suitably modulating the quantities of packages of the 180 mg dosage in order to be able to address the shortage of the 360 mg dosage.
It should be noted that the medicinal product MICOFEN ACID AC*100CPR 180 MG has never been lacking in the DPC distribution channel.
